Renaissance Technologies
ECYT

Renaissance Technologies’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Renaissance Technologies’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-194,500
Closed -$1.77M – 3673
2018
Q1 		$1.77M Sell
194,500
-99,080
-34% -$547K ﹤0.01% 2389
2017
Q4 		$1.26M Buy
293,580
+86,800
+42% +$414K ﹤0.01% 2577
2017
Q3 		$292K Buy
206,780
+86,056
+71% +$120K ﹤0.01% 2914
2017
Q2 		$181K Sell
120,724
-71,837
-37% -$154K ﹤0.01% 3015
2017
Q1 		$495K Buy
192,561
+142,461
+284% +$330K ﹤0.01% 2774
2016
Q4 		$128K Sell
50,100
-138,900
-73% -$399K ﹤0.01% 3065
2016
Q3 		$584K Buy
+189,000
New +$589K ﹤0.01% 2765
2016
Q2 		– Sell
-63,400
Closed -$197K – 3627
2016
Q1 		$197K Buy
63,400
+12,239
+24% +$40K ﹤0.01% 3095
2015
Q4 		$205K Sell
51,161
-21,538
-30% -$99.2K ﹤0.01% 2990
2015
Q3 		$333K Sell
72,699
-313,413
-81% -$1.64M ﹤0.01% 2736
2015
Q2 		$2M Buy
386,112
+7,012
+2% +$42.1K ﹤0.01% 2057
2015
Q1 		$2.37M Sell
379,100
-158,305
-29% -$914K 0.01% 1839
2014
Q4 		$3.38M Buy
537,405
+425,705
+381% +$2.59M 0.01% 1505
2014
Q3 		$679K Sell
111,700
-98,500
-47% -$673K ﹤0.01% 2208
2014
Q2 		$1.39M Buy
+210,200
New +$2.37M ﹤0.01% 1913
2013
Q4 		– Sell
-70,400
Closed -$938K – 3109
2013
Q3 		$938K Buy
70,400
+43,900
+166% +$694K ﹤0.01% 2041
2013
Q2 		$348K Buy
+26,500
New +$357K ﹤0.01% 2362

Other funds holding ECYT

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies's ECYT Position: Q2 2018 in Review

Renaissance Technologies sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2018, closing a stake of 194,500 shares — an estimated $1.77M sold.

Renaissance Technologies first reported a position in ECYT in Q2 2013 and held it in 17 quarters. The position peaked at $3.38M in Q4 2014. 114 funds tracked by Wall St. Rank hold ECYT as of Q2 2018.

  • Renaissance Technologies reported no remaining Endocyte, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Renaissance Technologies sold 194,500 Endocyte, Inc. Common Stock shares in Q2 2018, an estimated $1.77M.
  • Renaissance Technologies first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 17 quarters.
  • Renaissance Technologies's Endocyte, Inc. Common Stock position peaked at $3.38M in Q4 2014.
  • 114 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2018.

Based on Renaissance Technologies's 13F filing for Q2 2018, filed 13 Aug 2018.